Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announced the first patients were enrolled in Esprit, a global Phase 2 clinical ...

The neuromyelitis optica spectrum disorder market size in the 7MM is expected to show positive growth during the forecast period (2026--2036), mainly attributed to the increasing prevalence of NMOSD, ...

Globus Medical is rated a buy, driven by robust earnings growth, margin recovery, and strong management guidance following a ...

Explore neuroscience breakthroughs reshaping treatments for Alzheimer’s, Parkinson’s, PTSD, and other brain disorders.

New Zealanders with cancer and rare disorders will benefit from faster, locally delivered genomic testing through a new ...

Additional data analyses from Orbit and Cosmic Phase 3 studies of setrusumab (UX143) in osteogenesis imperfecta ongoingCash of $41.0 million as ...

Annualized height velocity of 9.05 cm/year (LS mean) for TransCon hGH-treated children was similar at Week 52 to daily somatropin-treated ...

With pressure from global competitors and recent changes in domestic policy threatening to undermine U.S. leadership in this ...

As assisted-suicide laws expand worldwide to include individuals diagnosed with mental disorders, the Citizens Commission on ...

The Trump administration recently celebrated one year of embracing the movement to Make America Healthy Again. Unfortunately, ...

How can the onset of psychotic symptoms characteristic of schizophrenia be explained? Despite their major and often irreversible impact on intellectual abilities and autonomy, the biological ...